Team:Evry/Achievements
From 2013.igem.org
(Difference between revisions)
Line 7: | Line 7: | ||
<br> | <br> | ||
<p> | <p> | ||
- | Here we detail how we fulfilled each of the <a href="https://2013.igem.org/Judging/Awards" target='_blank'>iGEM medal requirements</a>. | + | Here we detail how we fulfilled each of the <a href="https://2013.igem.org/Judging/Awards" target='_blank'><em>iGEM medal requirements</em></a>. |
</p> | </p> | ||
Line 17: | Line 17: | ||
<li class="tick">Help any registered iGEM team</li> | <li class="tick">Help any registered iGEM team</li> | ||
- | <li class="tick">As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a <a href="https://2013.igem.org/Team:Evry/Pill_design"> polymer-based capsule</a>. We also explored safety and ethics consequences of our project as the Human Practices studies: | + | <li class="tick">As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a <a href="https://2013.igem.org/Team:Evry/Pill_design"><em> polymer-based capsule</em></a>. We also explored safety and ethics consequences of our project as the Human Practices studies: |
<ol> | <ol> | ||
- | <li > We discussed the medical feasibility and implications of this treatment in a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" target='_blank'>series of interviews and discussions</a> with renowned experts on iron overload diseases.</li> | + | <li > We discussed the medical feasibility and implications of this treatment in a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" target='_blank'><em>series of interviews and discussions</em></a> with renowned experts on iron overload diseases.</li> |
- | <li>We carefully analyzed the <a href="https://2013.igem.org/Team:Evry/Safety" target='_blank'>safety issues</a> and potential consequences of our bacteria using consequence-based decision tree.</li> | + | <li>We carefully analyzed the <a href="https://2013.igem.org/Team:Evry/Safety" target='_blank'><em>safety issues</em></a> and potential consequences of our bacteria using consequence-based decision tree.</li> |
- | <li>We organized and hosted a <a href="https://2013.igem.org/Team:Evry/Seminar" target='_blank'>scientific conference</a> on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.</li> | + | <li>We organized and hosted a <a href="https://2013.igem.org/Team:Evry/Seminar" target='_blank'><em>scientific conference</em></a> on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.</li> |
- | <li> We prepared and disseminated a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" target='_blank'> patient perception survey</a> about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.</li> | + | <li> We prepared and disseminated a <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" target='_blank'><em> patient perception survey</em></a> about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.</li> |
- | <li>We wrote an extensive report on our <a href="https://2013.igem.org/Team:Evry/Philosophy">conclusions about | + | <li>We wrote an extensive report on our <a href="https://2013.igem.org/Team:Evry/Philosophy" target='_blank'>><em>conclusions about synthetic biology </em></a>, which is the fruit of our many discussions over the summer.</li> |
</ol> | </ol> | ||
Line 40: | Line 40: | ||
<p> | <p> | ||
<ul> | <ul> | ||
- | <li class="tick">We experimentally validated that the aceB-sfGFP biobrick acts as an iron-reponsive biosensor (<a href="https://2013.igem.org/Team:Evry/Results">see Fig 3 of Biology Results Section</a>). | + | <li class="tick">We experimentally validated that the aceB-sfGFP biobrick acts as an iron-reponsive biosensor (<a href="https://2013.igem.org/Team:Evry/Results" target='_blank'><em>see Fig 3 of Biology Results Section</em></a>). |
<li class="tick">We document the characterization of our aceB-sfGFP and other BioBricks in "Main Page" section of the Parts Registry. | <li class="tick">We document the characterization of our aceB-sfGFP and other BioBricks in "Main Page" section of the Parts Registry. | ||
- | <li class="tick">We submitted the following BioBricks parts to the iGEM Parts Registry. The 4 sGFP constructs function as <a href="https://2013.igem.org/Team:Evry/Sensor">iron sensors</a> and the lacI constructs are used to build a <a href="https://2013.igem.org/Team:Evry/Inverter">Fur-based genetic inverter</a> that activates gene expression in response to iron. These 8 Biobricks have been <a href="http://parts.igem.org/cgi/dna_transfer/batch_list.cgi?group_id=1475">received and accepted</a> by the Registry of Standard Biological Parts. | + | <li class="tick">We submitted the following BioBricks parts to the iGEM Parts Registry. The 4 sGFP constructs function as <a href="https://2013.igem.org/Team:Evry/Sensor" target='_blank'><em>iron sensors</em></a> and the lacI constructs are used to build a <a href="https://2013.igem.org/Team:Evry/Inverter" target='_blank'><em>Fur-based genetic inverter</em></a> that activates gene expression in response to iron. These 8 Biobricks have been <a href="http://parts.igem.org/cgi/dna_transfer/batch_list.cgi?group_id=1475" target='_blank'><em>received and accepted</em></a> by the Registry of Standard Biological Parts. |
<small> | <small> | ||
<ul> | <ul> | ||
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163102:Experience" target='_blank'>BBa_K1163102</a>: AceB-sfGFP characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163102:Experience" target='_blank'><em>BBa_K1163102</em></a>: AceB-sfGFP characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163103:Experience" target='_blank'>BBa_K1163103</a>: AceB-lacI characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163103:Experience" target='_blank'><em>BBa_K1163103</em></a>: AceB-lacI characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163105:Experience" target='_blank'>BBa_K1163105</a>: FepA-sfGFP characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163105:Experience" target='_blank'><em>BBa_K1163105</em></a>: FepA-sfGFP characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163106:Experience" target='_blank'>BBa_K1163106</a>: FepA-lacI characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163106:Experience" target='_blank'><em>BBa_K1163106</em></a>: FepA-lacI characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163108:Experience" target='_blank'>BBa_K1163108</a>: Fes-sfGFP characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163108:Experience" target='_blank'><em>BBa_K1163108</em></a>: Fes-sfGFP characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163109:Experience" target='_blank'>BBa_K1163109</a>: Fes-lacI characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163109:Experience" target='_blank'><em>BBa_K1163109</em></a>: Fes-lacI characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163111:Experience" target='_blank'>BBa_K1163111</a>: YncE-sfGFP characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163111:Experience" target='_blank'><em>BBa_K1163111</em></a>: YncE-sfGFP characterization |
- | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163112:Experience" target='_blank'>BBa_K1163112</a>: YncE-LacI characterization | + | <li><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1163112:Experience" target='_blank'><em>BBa_K1163112</em></a>: YncE-LacI characterization |
</ul> | </ul> | ||
- | </small> <li class="tick">We describe how our project has implications for <b><a href='https://2013.igem.org/Team:Evry/Safety' target='_blank'>safety</a></b> and <b><a href='https://2013.igem.org/Team:Evry/Philosophy" target='_blank'>ethics</a></b> | + | </small> <li class="tick">We describe how our project has implications for <b><a href='https://2013.igem.org/Team:Evry/Safety' target='_blank'><em>safety</em></a></b> and <b><a href='https://2013.igem.org/Team:Evry/Philosophy" target='_blank'><em>ethics</em></a></b> |
</ul> | </ul> | ||
Line 67: | Line 67: | ||
<p> | <p> | ||
<ul> | <ul> | ||
- | <li class="tick">We <a href="https://igem.org/Team_List?year=2013"> registered our team</a> for iGEM 2013 and are attending the European Regional Jamboree. | + | <li class="tick">We <a href="https://igem.org/Team_List?year=2013"><em> registered our team</em></a> for iGEM 2013 and are attending the European Regional Jamboree. |
- | <li class="tick">We completed and submitted the <a href='https://igem.org/2013_Judging_Form?id=1163' target='_blank'>Judging form</a>. | + | <li class="tick">We completed and submitted the <a href='https://igem.org/2013_Judging_Form?id=1163' target='_blank'><em>Judging form</em></a>. |
- | <li class="tick">We made a comprehensive and accessible <a href="https://2013.igem.org/Team:Evry">iGEM Evry 2013 Wiki</a> to convey our educational and scientific advances. | + | <li class="tick">We made a comprehensive and accessible <a href="https://2013.igem.org/Team:Evry"><em>iGEM Evry 2013 Wiki</em></a> to convey our educational and scientific advances. |
<li class="tick">We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.</b> | <li class="tick">We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.</b> | ||
- | <li class="tick">We <a href='https://2013.igem.org/Team:Evry/Parts' target='_blank'>document 22 BioBricks</a></b> used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements). | + | <li class="tick">We <a href='https://2013.igem.org/Team:Evry/Parts' target='_blank'><em>document 22 BioBricks</em></a></b> used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements). |
</ul> | </ul> | ||
Revision as of 13:35, 4 October 2013
iGEM Evry 2013 achievements
Here we detail how we fulfilled each of the iGEM medal requirements.
Gold Medal (requires any one of the following goals)
- Improve the function of an existing BioBrick Part or Device: we characterize the LacO-RFP BioBrick and improve it by integrating it with an aceB-LacI iron sensor.
- Help any registered iGEM team
- As our project involves treating a human genetic disorder using genetically-engineered bacteria, it has numerous implications for human health, safety and security, and ethics. To enable safe delivery of therapeutic bacteria to the human intestine, we designed and constructed a polymer-based capsule. We also explored safety and ethics consequences of our project as the Human Practices studies:
- We discussed the medical feasibility and implications of this treatment in a series of interviews and discussions with renowned experts on iron overload diseases.
- We carefully analyzed the safety issues and potential consequences of our bacteria using consequence-based decision tree.
- We organized and hosted a scientific conference on iron overload disorders and perceptions of our our project on 18 September 2013. This conference was attended by both medical experts and iron disorder patients.
- We prepared and disseminated a patient perception survey about how our treatment could potentially help hemochromatosis patients. We received and analyzed the results from over 250 patients who responded to our survey.
- We wrote an extensive report on our >conclusions about synthetic biology , which is the fruit of our many discussions over the summer.
Silver Medal (requires each of the four following goals)
- We experimentally validated that the aceB-sfGFP biobrick acts as an iron-reponsive biosensor (see Fig 3 of Biology Results Section).
- We document the characterization of our aceB-sfGFP and other BioBricks in "Main Page" section of the Parts Registry.
- We submitted the following BioBricks parts to the iGEM Parts Registry. The 4 sGFP constructs function as iron sensors and the lacI constructs are used to build a Fur-based genetic inverter that activates gene expression in response to iron. These 8 Biobricks have been received and accepted by the Registry of Standard Biological Parts.
- BBa_K1163102: AceB-sfGFP characterization
- BBa_K1163103: AceB-lacI characterization
- BBa_K1163105: FepA-sfGFP characterization
- BBa_K1163106: FepA-lacI characterization
- BBa_K1163108: Fes-sfGFP characterization
- BBa_K1163109: Fes-lacI characterization
- BBa_K1163111: YncE-sfGFP characterization
- BBa_K1163112: YncE-LacI characterization
- We describe how our project has implications for safety and ethics
Bronze Medal (requires each of the five following goals)
- We registered our team for iGEM 2013 and are attending the European Regional Jamboree.
- We completed and submitted the Judging form.
- We made a comprehensive and accessible iGEM Evry 2013 Wiki to convey our educational and scientific advances.
- We will present a poster and give an oral presentation at the iGEM European Jamboree in Lyon, France.
- We document 22 BioBricks used in our project and submit 8 news BioBricks to the Parts Registry (see 8 submitted Biobricks in Silver Medal Requirements).